Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2017-08-03Clinical Trial Update: FNA Tumor Sampling for CD137 Modulation: A Pilot Study
Termination update for a pilot study evaluating FNA tumor sampling for CD137 modulation in cancer patients.
-
CLINICAL_TRIALS trial_result · 2017-08-01Clinical Trial Update: Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation [Phase 2]
Phase 2 clinical trial update evaluating upfront plerixafor in autologous transplantation and its clinical and economic impact in Non-Hodgki…
-
CLINICAL_TRIALS trial_result · 2017-07-26Clinical Trial Update: A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 [Phase 1]
Phase I dose-escalation study evaluating the safety and biological activity of recombinant human interleukin-18 in Non-Hodgkin lymphoma; the…
-
CLINICAL_TRIALS trial_result · 2017-07-25Clinical Trial Update: Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement [Phase 1]
Phase 1 trial assessing the safety and efficacy of an iodine-131 labeled anti-B1 antibody in non-Hodgkin lymphoma patients with >25% bone ma…
-
CLINICAL_TRIALS trial_result · 2017-07-18Clinical Trial Update: Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 non-inferiority trial comparing XM02 (Granix) and filgrastim (Neupogen) when used with plerixafor for autologous stem cell mobiliz…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-07-17Clinical Trial Update: Preservation of Ovarian Function After Hematopoietic Cell Transplant [Phase 2]
Phase 2 trial investigating preservation of ovarian function after hematopoietic cell transplantation in patients with hematologic cancers; …
-
CLINICAL_TRIALS trial_result · 2017-07-14Clinical Trial Update: Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
Clinical trial evaluating the combination of rituximab and liposomal doxorubicin in relapsed or refractory non-Hodgkin lymphoma across Phase…
-
CLINICAL_TRIALS trial_result · 2017-07-02Clinical Trial Update: Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells [Phase 2]
Phase 2 trial investigating rituximab with combination chemotherapy, G-CSF, and plerixafor for autologous stem cell mobilization in non-Hodg…
-
CLINICAL_TRIALS trial_result · 2017-06-28Clinical Trial Update: Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma [Phase 1]
The Phase 1/1b study of TRU-016 in patients with previously treated Chronic Lymphocytic Leukemia or select subtypes of Non-Hodgkin's Lymphom…
-
CLINICAL_TRIALS trial_result · 2017-06-20Clinical Trial Update: A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) [Phase 1]
Phase 1 dose-escalation study of MK-8776 (SCH 900776) with and without gemcitabine in solid tumors or lymphoma completed; results posted in …
-
CLINICAL_TRIALS trial_result · 2017-06-16Clinical Trial Update: A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma [Phase 1]
This Phase 1 trial investigates escalating doses of polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic ly…
-
CLINICAL_TRIALS trial_result · 2017-06-16Clinical Trial Update: Copanlisib Pharmacodynamic Study [Phase 1]
Phase 1 pharmacodynamic study of copanlisib in non-Hodgkin lymphoma has completed. The document indicates this early-stage trial produced ph…
-
CLINICAL_TRIALS trial_result · 2017-06-07Clinical Trial Update: A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) [Phase 3]
Phase 3 trial comparing obinutuzumab plus chemotherapy vs rituximab plus chemotherapy in untreated advanced indolent non-Hodgkin's lymphoma;…
-
CLINICAL_TRIALS trial_result · 2017-06-06Clinical Trial Update: Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies [Phase 1, Phase 2]
Phase 1/2 study evaluating plerixafor (AMD3100) as a stem cell mobilizer for transplantation from a sibling donor in various hematologic mal…
-
CLINICAL_TRIALS trial_result · 2017-06-06Clinical Trial Update: A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g) [Phase 2]
Phase 2 study evaluating PRO95780 in combination with Rituximab in patients with Non-Hodgkin lymphoma that progressed after prior Rituximab …
-
CLINICAL_TRIALS trial_result · 2017-06-05Clinical Trial Update: Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT [Phase 2]
Phase 2 trial of sirolimus and mycophenolate mofetil as graft-versus-host disease prophylaxis in myeloablative, matched related donor hemato…
-
CLINICAL_TRIALS trial_result · 2017-06-01Clinical Trial Update: BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL) [Phase 3]
Phase 3 clinical trial update for BBR 2778 in relapsed, aggressive non-Hodgkin's lymphoma has completed and results were posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-05-30Clinical Trial Update: Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma [Phase 2]
This Phase 2 clinical trial update evaluates whether rituximab can help achieve PCR-negative leukapheresis products in patients with relapse…
-
CLINICAL_TRIALS trial_result · 2017-05-30Clinical Trial Update: Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer [Phase 2]
Phase 2 trial evaluating a conditioning regimen with alemtuzumab, fludarabine phosphate, and total-body irradiation followed by cyclosporine…
-
CLINICAL_TRIALS trial_result · 2017-05-30Clinical Trial Update: Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) [Phase 2]
Phase 2 trial evaluating nivolumab in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after autologous stem cell transplant fai…
-
CLINICAL_TRIALS trial_result · 2017-05-24Clinical Trial Update: Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer [NA]
Clinical trial update reports results of a conditioning regimen using fludarabine and total-body irradiation followed by donor stem cell tra…
-
CLINICAL_TRIALS trial_result · 2017-05-24Clinical Trial Update: Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 clinical trial evaluating a multi-modality approach combining Yttrium-90 ibritumomab tiuxetan, fludarabine, radiation therapy, and d…
-
CLINICAL_TRIALS trial_result · 2017-05-24Clinical Trial Update: Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma [Phase 2]
Phase 2 study evaluating the combination of bendamustine hydrochloride, etoposide, dexamethasone, and filgrastim for peripheral blood stem c…
-
CLINICAL_TRIALS trial_result · 2017-05-23Clinical Trial Update: Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim [Phase 1]
Open-label Phase 1 study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of Aurixim in lymphoma patients; study compl…
-
CLINICAL_TRIALS trial_result · 2017-05-22Clinical Trial Update: Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma [Phase 2]
Phase 2 study evaluating rituximab plus dexamethasone in patients with low-grade non-Hodgkin lymphoma, including follicular and marginal zon…